Klaria Pharma Publishes Prospectus for Rights Issue
Klaria Pharma Holding AB has published an EU prospectus for a planned rights issue aiming to raise approximately SEK 147.6 million.
Swedish pharmaceutical company Klaria Pharma Holding AB has published an EU follow-on prospectus concerning a planned rights issue. The company aims to raise approximately SEK 147.6 million (around EUR 13 million) through this issuance.
The funds are intended for the company's general business activities, with a focus on financing clinical trials and supporting commercial operations. Klaria Pharma is developing treatments for pain management and central nervous system disorders.
The rights issue is being offered to the company's existing shareholders, who will receive subscription rights proportional to their holdings. Each subscription right will entitle the holder to subscribe for new units, comprising shares and warrants.
Klaria Pharma has previously stated its strategic objectives involve advancing its drug development pipeline. This capital infusion is considered a crucial step in pursuing these goals and potentially bringing new therapies to market.